Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

FDA clears Surrozen's IND for for DME therapy

15 October 2026 · By · Wire by Fusion42

Published

15 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at glance.eyesoneyecare.com →

◆ Verified

Fusion42 · 16 October 2026 · Fusion42 review

Surrozen, Inc. has received FDA clearance for its IND application to begin clinical trials of SZN-8141, an investigational bifunctional antibody targeting diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The company plans to initiate the phase 1b/2a DUET study in Q4 2026 and expects to raise approximately $95.1 million to support clinical development and operations.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must act on Surrozen’s IND clearance now because their clinical trial window opens imminently, unlocking a $95 million funding round that may shift competitive dynamics in retinal disease therapeutics.

◆ Coverage

1 source · 15 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfda-clearanceind-approvalclinical-trialsdiabetic-macular-edemafundraising